While the tumor necrosis factor (TNF) inhibiting drugs have been a great addition in the treatment of rheumatoid arthritis, it must be remembered that they have a failure rate in up to 40% of patients. Thus, B-lymphocyte cells became one more target; TNF is not the only thing that can be attacked and give improvement in rheumatoid arthritis.
Rituxan is one approach to targeting those B cells. Rituxan does this by depleting B cells, cells participating in the abnormal immune system in...
